Topics
- Drugs targeting molecular pathways that are common to cardiovascular disease and diabetes
- Damage to the cardiovascular system
- Inflammation on the progression of type 2 diabetes throughout the body
- Drugs to reduce the build up of fats and lipids in blood vessels including DPP-4 analogues and GLP-1 inhibitors
- Clinical trials into monoclonal antibody treatments for diabetic retinopathy
- Next-generation insulins to control diabetics
- Retinal scanning techniques to assess the impact of therapeutic interventions for diabetic retinopathy
- The central nervous system and diabetics with retinal complications
- Results from clinical trials to treat diabetic retinopathy (EUCLID, RASS, DIRECT, FIELD)
- Advances in optical coherence tomography (OCT) for diabetic retinopathy
Who should Attend
Managers, executives, Scientists and Clinicians involved in Retinal Diseases, Diabetes & Obesity, Clinical R&D, Endocrinology and Metabolic Diseases, Ophthalmology, Visual Science and Vision Research, Anti-Diabetic Agents & Advanced Diabetes Systems, Cardiovascular and Gastrointestinal Diseases, Imaging and Translational Medicine, Biomarkers, Monoclonal Antibodies, Drug Development, New Products Global Marketing, Molecular Neuroscience, Venture Capital, Business Development and Licensing & Partnership.
